tetano
Editor, Senior Moderator
Virology. 2016 Mar 8;492:197-203. doi: 10.1016/j.virol.2016.02.024. [Epub ahead of print]
[h=1]A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.[/h] Liu F[SUP]1[/SUP], Sun X[SUP]1[/SUP], Fairman J[SUP]2[/SUP], Lewis DB[SUP]3[/SUP], Katz JM[SUP]1[/SUP], Levine M[SUP]1[/SUP], Tumpey TM[SUP]1[/SUP], Lu X[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A (H5N1) viruses continue to pose a public health threat. As inactivated H5N1 vaccines are poorly immunogenic, adjuvants are needed to improve the immunogenicity of H5N1 vaccine in humans. Here, we investigated the immunogenicity and cross-protective efficacy in ferrets of a clade 2.2-derived vaccine with addition of JVRS-100, an adjuvant consisting of cationic liposome-DNA complexes (CLDC). After the first vaccination, significantly higher levels of hemagglutination-inhibition (HAI) and neutralizing antibody titers were detected in ferrets immunized with adjuvanted vaccine compared to unadjuvanted vaccine. Following a second dose of adjuvanted vaccine, HAI antibody titers of≥40 were detected against viruses from multiple H5N1 clades. HAI antibodies against newly isolated H5N2 and H5N8 viruses were also augmented by JVRS-100. Ferrets were challenged with a heterologous H5N1 virus. All ferrets that received two doses of adjuvanted vaccine exhibited mild illness, significantly reduced nasal wash virus titers and protection from lethal challenge. In contrast, ferrets that received unadjuvanted vaccine showed greater weight loss, high viral titers and 3 of 6 animals succumbed to the lethal challenge. Our results indicate that the addition of JVRS-100 to H5N1 vaccine enhanced immunogenicity and cross-protection against lethal H5N1 virus disease in ferrets. JVRS-100 warrants further investigation as a potential adjuvant for influenza vaccines.
Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Antibody response; CLDC adjuvant; Cross-protection; Ferrets; Influenza A (H5N1) vaccine
PMID: 26967975 [PubMed - as supplied by publisher]
[h=1]A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.[/h] Liu F[SUP]1[/SUP], Sun X[SUP]1[/SUP], Fairman J[SUP]2[/SUP], Lewis DB[SUP]3[/SUP], Katz JM[SUP]1[/SUP], Levine M[SUP]1[/SUP], Tumpey TM[SUP]1[/SUP], Lu X[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A (H5N1) viruses continue to pose a public health threat. As inactivated H5N1 vaccines are poorly immunogenic, adjuvants are needed to improve the immunogenicity of H5N1 vaccine in humans. Here, we investigated the immunogenicity and cross-protective efficacy in ferrets of a clade 2.2-derived vaccine with addition of JVRS-100, an adjuvant consisting of cationic liposome-DNA complexes (CLDC). After the first vaccination, significantly higher levels of hemagglutination-inhibition (HAI) and neutralizing antibody titers were detected in ferrets immunized with adjuvanted vaccine compared to unadjuvanted vaccine. Following a second dose of adjuvanted vaccine, HAI antibody titers of≥40 were detected against viruses from multiple H5N1 clades. HAI antibodies against newly isolated H5N2 and H5N8 viruses were also augmented by JVRS-100. Ferrets were challenged with a heterologous H5N1 virus. All ferrets that received two doses of adjuvanted vaccine exhibited mild illness, significantly reduced nasal wash virus titers and protection from lethal challenge. In contrast, ferrets that received unadjuvanted vaccine showed greater weight loss, high viral titers and 3 of 6 animals succumbed to the lethal challenge. Our results indicate that the addition of JVRS-100 to H5N1 vaccine enhanced immunogenicity and cross-protection against lethal H5N1 virus disease in ferrets. JVRS-100 warrants further investigation as a potential adjuvant for influenza vaccines.
Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Antibody response; CLDC adjuvant; Cross-protection; Ferrets; Influenza A (H5N1) vaccine
PMID: 26967975 [PubMed - as supplied by publisher]